261 related articles for article (PubMed ID: 34445110)
1. Synergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer.
Jeong MS; Lee KW; Choi YJ; Kim YG; Hwang HH; Lee SY; Jung SE; Park SA; Lee JH; Joo YJ; Cho SG; Ko SG
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445110
[TBL] [Abstract][Full Text] [Related]
2. SH003 and Docetaxel Show Synergistic Anticancer Effects by Inhibiting EGFR Activation in Triple-Negative Breast Cancer.
Choi YJ; Lee K; Yoon JH; Cho SG; Kim YG; Jeong M; Hwang HH; Lee SY; Jung SE; Ko SG
Biomed Res Int; 2022; 2022():3647900. PubMed ID: 35572726
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
Tang N; Zhang Q; Fang S; Han X; Wang Z
Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
6. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
[TBL] [Abstract][Full Text] [Related]
7.
Batbold U; Liu JJ
Molecules; 2021 Nov; 26(23):. PubMed ID: 34885780
[TBL] [Abstract][Full Text] [Related]
8. MMPP Attenuates Non-Small Cell Lung Cancer Growth by Inhibiting the STAT3 DNA-Binding Activity
Son DJ; Zheng J; Jung YY; Hwang CJ; Lee HP; Woo JR; Baek SY; Ham YW; Kang MW; Shong M; Kweon GR; Song MJ; Jung JK; Han SB; Kim BY; Yoon DY; Choi BY; Hong JT
Theranostics; 2017; 7(18):4632-4642. PubMed ID: 29158850
[No Abstract] [Full Text] [Related]
9. Enhanced anticancer effects of Scutellaria barbata D. Don in combination with traditional Chinese medicine components on non-small cell lung cancer cells.
Wang Q; Acharya N; Liu Z; Zhou X; Cromie M; Zhu J; Gao W
J Ethnopharmacol; 2018 May; 217():140-151. PubMed ID: 29458146
[TBL] [Abstract][Full Text] [Related]
10. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
11. SH003 reverses drug resistance by blocking signal transducer and activator of transcription 3 (STAT3) signaling in breast cancer cells.
Seo HS; Ku JM; Lee HJ; Woo JK; Cheon C; Kim M; Jang BH; Shin YC; Ko SG
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 28864784
[TBL] [Abstract][Full Text] [Related]
12. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF
J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
[TBL] [Abstract][Full Text] [Related]
13. Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC.
Hu R; Li T; Hui K; Chen Z; Wang N; Wu X; Ge L; Zhou L
Mol Med Rep; 2020 Nov; 22(5):3935-3943. PubMed ID: 32901884
[TBL] [Abstract][Full Text] [Related]
14. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
[TBL] [Abstract][Full Text] [Related]
15. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
[TBL] [Abstract][Full Text] [Related]
16. Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Phan AN; Hua TN; Kim MK; Vo VT; Choi JW; Kim HW; Rho JK; Kim KW; Jeong Y
Oncotarget; 2016 Aug; 7(34):54702-54713. PubMed ID: 27419630
[TBL] [Abstract][Full Text] [Related]
17. Induction of apoptosis by morusin in human non-small cell lung cancer cells by suppression of EGFR/STAT3 activation.
Park HJ; Min TR; Chi GY; Choi YH; Park SH
Biochem Biophys Res Commun; 2018 Oct; 505(1):194-200. PubMed ID: 30243717
[TBL] [Abstract][Full Text] [Related]
18. Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.
Zhu F; Dai C; Fu Y; Loo JF; Xia D; Gao SP; Ma Z; Chen Z
Oncotarget; 2016 Feb; 7(8):9462-76. PubMed ID: 26843613
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel-loaded exosomes for targeting non-small cell lung cancer: preparation and evaluation
Wang Y; Guo M; Lin D; Liang D; Zhao L; Zhao R; Wang Y
Drug Deliv; 2021 Dec; 28(1):1510-1523. PubMed ID: 34263685
[TBL] [Abstract][Full Text] [Related]
20. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]